Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: Aβ-Tau Synergy Hypotheses\n\n## Executive Summary\n\nThe translational landscape for Aβ-tau synergy hypotheses is increasingly tractable given recent trial failures and biomarker validation. I'll identify high-potential hypotheses, address feasibility constraints, and propose mechanistic refinements.\n\n---\n\n## 1. Top 3 Hypotheses by Translational Potential\n\n### Hypothesis A: Tau Dendritic Missorting as Gain-of-Toxic-Function (Highest Potential)\n\n**Core Mechanism:**\nAβ triggers tau hyperphosphorylation and missorting from axons to dendrites, where it enhances NMDA receptor trafficking and destabilizes dendritic spines. Critically, once tau is missorted, this state persists independently of ongoing Aβ pathology. Anti-Aβ monotherapy fails because it cannot reverse established tau missorting; tau remains at dendritic spines where it maintains excitotoxic signaling even as Aβ burden decreases.\n\n**Translational Rationale:**\nThis hypothesis is highly actionable because:\n\n- Existing drugs targeting tau localization (e.g., tau antibodies like semorinemab targeting extracellular tau, which may intercept missorted tau at synapses) are already in trials\n- The excitotoxicity phenotype is measurable with EEG/polysomnography (evidence of cortical hyperexcitability in AD)\n- Genetic validation exists: MAPT mutations causing frontotemporal dementia demonstrate that tau dysfunction alone can cause neurodegeneration, validating tau as a therapeutic target independent of Aβ\n- The mechanism explains why anti-Aβ trials in symptomatic patients fail while prevention trials (DIAN-TU) show some signals—earlier intervention prevents tau missorting before it becomes self-sustaining\n\n**Patient Population Fit:** Prodromal-to-mild AD patients with elevated CSF p-tau181/217 and positive amyloid PET. These patients have established tau pathology but may not yet have reached the threshold where tau pathology becomes fully Aβ-independent.\n\n**Safety Considerations",
  "tokens_used": "496"
}